These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38324858)

  • 1. Differences Between Two Distinct Hypertrophic Cardiac Conditions: Fabry Disease versus Hypertrophic Cardiomyopathy.
    Akhan O; Kış M; Güzel T; Zoghi M
    Arq Bras Cardiol; 2024 Jan; 121(1):e20230229. PubMed ID: 38324858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obstructive - Nonobstructive hypertrophic cardiomyopathy: differences and predictors.
    Akhan O; Kis M; Guzel T; Dogdus M; Zoghi M
    Acta Cardiol; 2024 Jun; 79(4):444-453. PubMed ID: 37811570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of left atrial size and function in hypertrophic cardiomyopathy and in Fabry disease with left ventricular hypertrophy.
    Saccheri MC; Cianciulli TF; Challapa Licidio W; Lax JA; Beck MA; Morita LA; Gagliardi JA;
    Echocardiography; 2018 May; 35(5):643-650. PubMed ID: 29457264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of Electrocardiography to Distinguish Fabry Disease from Sarcomeric Hypertrophic Cardiomyopathy.
    Antezana-Chavez E; Cianciulli TF; Hadid CL; Toro DD; Celano L; Saccheri MC; Baez KG; Lopez CA; Labadet CD; Gagliardi JA
    Am J Cardiol; 2022 Sep; 178():131-136. PubMed ID: 35810008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myocardial infarction with non-obstructive coronary arteries in hypertrophic cardiomyopathy vs Fabry disease.
    Graziani F; Lillo R; Biagini E; Limongelli G; Autore C; Pieroni M; Lanzillo C; Calò L; Musumeci MB; Ingrasciotta G; Minnucci M; Ditaranto R; Milazzo A; Zocchi C; Rubino M; Lanza GA; Olivotto I; Crea F
    Int J Cardiol; 2022 Dec; 369():29-32. PubMed ID: 35931207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early segmental relaxation abnormalities in hypertrophic cardiomyopathy for differential diagnostic of patients with left ventricular hypertrophy.
    Voigt C; Münch J; Avanesov M; Suling A; Witzel K; Lund G; Patten M
    Clin Cardiol; 2017 Nov; 40(11):1026-1032. PubMed ID: 28741295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy.
    Chimenti C; Pieroni M; Morgante E; Antuzzi D; Russo A; Russo MA; Maseri A; Frustaci A
    Circulation; 2004 Aug; 110(9):1047-53. PubMed ID: 15313943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy.
    Kubo T; Ochi Y; Baba Y; Hirota T; Tanioka K; Yamasaki N; Yoshimitsu M; Higuchi K; Takenaka T; Nakajima K; Togawa T; Tsukimura T; Sano S; Tei C; Sakuraba H; Kitaoka H
    J Cardiol; 2017 Jan; 69(1):302-307. PubMed ID: 27554049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinguishing left ventricular hypertrophy from hypertrophic cardiomyopathy in adolescents: a longitudinal observation study.
    Forså MI; Smedsrud MK; Haugaa KH; Bjerring AW; Früh A; Sarvari SI; Landgraff HW; Hallén J; Edvardsen T
    Eur J Prev Cardiol; 2024 Mar; 31(5):591-598. PubMed ID: 37992187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation between Fabry disease and hypertrophic cardiomyopathy with cardiac T1 mapping.
    Deborde E; Dubourg B; Bejar S; Brehin AC; Normant S; Michelin P; Dacher JN
    Diagn Interv Imaging; 2020 Feb; 101(2):59-67. PubMed ID: 31519470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertensive heart disease versus hypertrophic cardiomyopathy: multi-parametric cardiovascular magnetic resonance discriminators when end-diastolic wall thickness ≥ 15 mm.
    Rodrigues JC; Rohan S; Ghosh Dastidar A; Harries I; Lawton CB; Ratcliffe LE; Burchell AE; Hart EC; Hamilton MC; Paton JF; Nightingale AK; Manghat NE
    Eur Radiol; 2017 Mar; 27(3):1125-1135. PubMed ID: 27368925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Right ventricular myocardial diastolic dysfunction in different kinds of cardiac hypertrophy: analysis by pulsed Doppler tissue imaging.
    Galderisi M; Severino S; Caso P; Cicala S; Petrocelli A; De Simone L; Mininni N; de Divitiis O
    Ital Heart J; 2001 Dec; 2(12):912-20. PubMed ID: 11838339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships between left ventricular mass and QRS duration in diverse types of left ventricular hypertrophy.
    Domain G; Chouquet C; Réant P; Bongard V; Vedis T; Rollin A; Mandel F; Delasnerie H; Voglimacci-Stephanopoli Q; Mondoly P; Beneyto M; Cariou E; Fournier P; Delmas C; Galinier M; Carrié D; Lafitte S; Lairez O; Ferrières J; Cochet H; Maury P
    Eur Heart J Cardiovasc Imaging; 2022 Mar; 23(4):560-568. PubMed ID: 33842939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endomyocardial radial strain imaging and left ventricular relaxation abnormalities in patients with hypertrophic cardiomyopathy or hypertensive left ventricular hypertrophy.
    Minoshima M; Noda A; Nishizawa T; Hara Y; Sugiura M; Iino S; Nagata K; Koike Y; Murohara T
    Circ J; 2009 Dec; 73(12):2294-9. PubMed ID: 19838000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and Clinical Characteristics of Fabry Disease in Chinese Patients With Hypertrophic Cardiomyopathy.
    Xiao Y; Sun Y; Tian T; Wang TJ; Zhao RX; Zhang Y; Wang LP; Liu YX; Lu CX; Zhou XL; Yang WX
    Am J Med Sci; 2021 Sep; 362(3):260-267. PubMed ID: 34266644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology.
    Savostyanov K; Pushkov A; Zhanin I; Mazanova N; Trufanov S; Pakhomov A; Alexeeva A; Sladkov D; Asanov A; Fisenko A
    Orphanet J Rare Dis; 2022 May; 17(1):199. PubMed ID: 35578305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of right ventricular contractile abnormalities in hypertrophic cardiomyopathy versus hypertensive heart disease using two dimensional strain imaging: a cross-sectional study.
    Afonso L; Briasoulis A; Mahajan N; Kondur A; Siddiqui F; Siddiqui S; Alesh I; Cardozo S; Kottam A
    Int J Cardiovasc Imaging; 2015 Dec; 31(8):1503-9. PubMed ID: 26245470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography.
    Kato TS; Noda A; Izawa H; Yamada A; Obata K; Nagata K; Iwase M; Murohara T; Yokota M
    Circulation; 2004 Dec; 110(25):3808-14. PubMed ID: 15583080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy.
    Gaggl M; Lajic N; Heinze G; Voigtländer T; Sunder-Plassmann R; Paschke E; Fauler G; Sunder-Plassmann G; Mundigler G
    Int J Med Sci; 2016; 13(5):340-6. PubMed ID: 27226774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galectin-3 levels in patients with hypertrophic cardiomyopathy and its relationship with left ventricular mass index and function.
    Yakar Tülüce S; Tülüce K; Çil Z; Emren SV; Akyıldız Zİ; Ergene O
    Anatol J Cardiol; 2016 May; 16(5):344-8. PubMed ID: 26488381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.